"The Lancet" announced the final effective rate of China's first adenovirus vector vaccine: a critical protection rate of 96%, no serious adverse reactions occurred

CCTV, Beijing, December 24th (Reporter Ma Kejia) Recently, the international authoritative medical journal "The Lancet" released China's first adenovirus vector vaccine-Cansino Bio-Recombinant Novel Coronavirus Vaccine (Type 5 Adenovirus Vector) ) The final efficiency and interim safety analysis results of Kevisa's global multi-center phase III clinical trial
.

The data showed that 14 days after vaccination, the critical illness protection rate was 96.
0%, and the overall protection rate was 63.
7%, reaching the standard for the protection rate of the new crown vaccine recommended by the World Health Organization.
No serious vaccine-related adverse reactions occurred
.

Phase III clinical data of the largest sample of China's new crown vaccine

Up to now, this phase III clinical trial is the largest clinical trial of the new crown vaccine produced in China
.

It is understood that the study carried out a randomized, double-blind, placebo-controlled global multi-center phase III clinical trial in 5 countries including Argentina, Chile, Mexico, Pakistan, and Russia.
A total of 66 centers participated in the study
.

A total of 45,000 subjects were enrolled in this study, covering low-income, middle-income and high-income areas, including elderly, obese, and low-weight people, and the proportion of elderly people included is the current domestic new crown vaccine inclusion rate The highest (greater than 10%)

No vaccine can guarantee 100% protection, especially a vaccine against a constantly mutating pathogen like the new coronavirus
.

In other words, after being vaccinated with the new crown vaccine, it is still possible to be infected by the new crown virus or even get sick

It is worth mentioning that this clinical trial is distributed in five countries around the world with a period of more than 12 months.
Up to now, the long-term safety observation of the clinical trial is still in progress
.

Compared with other new crown vaccines, the test situation is more complicated

Data show that vaccination with 1 dose of Keweisha is well tolerated and safe
.

And the common adverse reactions are mostly mild to moderate, such as pain at the injection site, headache, fatigue and other symptoms, which basically disappear within a week after vaccination

Continued efforts for the global war "epidemic" inhalable vaccines have achieved phased results

It is understood that CanSino Bio's recombinant new coronavirus vaccine (type 5 adenovirus vector) Keweisha is currently the only single-dose new coronavirus vaccine in China.
Using the adenovirus vector technology route, it can induce humoral immunity and cellular immunity at the same time
.

Up to now, the vaccine has obtained emergency use authorization or conditional marketing approval in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Pakistan, Indonesia, Malaysia and other countries, helping the world to quickly build an immune barrier

With the development of the epidemic and the emergence of a new variant of Omi Keron, the World Health Organization (WHO) has issued interim guidance for the allogeneic enhancement of the new crown vaccine based on existing research data
.

The guidelines are based on the recommendations recently made by the WHO Strategic Advisory Panel

Insiders believe that more and more studies have proved the safety and effectiveness of vaccine heterogeneous enhancement, and this enhanced vaccination strategy may accelerate under the influence of Omi Keron mutant strain
.

Previously, Academician Zhong Nanshan also showed the antibody level change data after the sequential strengthening of the recombinant new crown vaccine at the 2021 Greater Bay Area Science Forum: 3-6 months after inoculation with 2 doses of inactivated vaccines, it was strengthened with CanSino Bio-Adenovirus vector vaccine.
The antibody will be about 200 times higher than before the boost
.

Zhong Nanshan suggested that the effect of vaccination with different types of vaccines may be better

In addition to the intramuscular injection form, CanSino Bio has also developed an adenovirus vector vaccine for inhalation, and has carried out sequential and strengthened related research
.

The results show that after inoculating 2 doses of inactivated vaccine and then boosting 1 dose of adenovirus carrier new crown vaccine (inhalation dosage form), it can induce extremely high antibody levels and cellular immune responses, and the neutralizing antibody level will increase by about 300 times after boosting

It is reported that the inhaled new crown vaccine is currently the only vaccine with triple protection of humoral immunity, cellular immunity and mucosal immunity.
It trains the body's immune memory function by imitating the natural infection of the virus
.
The inhaled dosage form does not require injections, avoids local adverse reactions, increases the population's willingness to vaccinate, and is expected to further increase the immunization coverage rate
.
Zhu Tao, chief scientific officer of Cansino Bio, once said that an adenovirus vector vaccine for inhalation can also be developed for Omi Keron
.

From a global perspective, regardless of the current degree of mutation, transmission and pathogenic mechanisms are still within the scope of recognition, and vaccines of various technical routes around the world still have a certain protective effect on various mutant strains
.